Literature DB >> 3881903

Effects of calcium-channel blockers on myocardial preservation during experimental acute myocardial infarction.

K A Reimer, R B Jennings.   

Abstract

Calcium antagonists have become accepted agents for the attenuation of myocardial ischemia when it becomes manifest as angina pectoris. However, it is not known whether these agents can protect ischemic myocardium during the early evolution of an acute myocardial infarct. Calcium antagonists could potentially improve myocardial perfusion, by relieving coronary spasm or improving collateral blood flow, and reduce the energy demands of the ischemic myocardium either directly or by reducing heart rate or contractility. In some studies, calcium antagonists have decreased the rate of adenosine triphosphate depletion in ischemia and reduced functional or structural indexes of ischemic injury after relatively brief periods (up to 2 hours) of injury. We have assessed the ability of verapamil to protect severely ischemic myocardium in dogs with a 40-minute test period of circumflex occlusion followed by reperfusion. After 4 days of recovery, infarcts were sized by histologic methods. Untreated dogs had subendocardial infarcts (the more moderately ischemic subepicardial region being salvaged by reperfusion). Pretreatment with verapamil reduced the size of these subendocardial infarcts from 34 +/- 8 to 8 +/- 3% of the ischemic circumflex vascular bed (anatomic area at risk). Thus, verapamil prevented cell death in a substantial proportion of the severely ischemic subendocardial region that otherwise would have died as a result of the 40-minute test period of ischemia. To establish whether verapamil could prevent cell death for a longer period of time in the less severely ischemic subepicardial region, a 3-hour period of coronary occlusion with reperfusion was studied.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881903     DOI: 10.1016/0002-9149(85)90619-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Combined effect of glucose and verapamil in experimental cardioplegia.

Authors:  E Hochhauser; Y Barak; S Einav; S Cohen; B Vidne
Journal:  Tex Heart Inst J       Date:  1986-03

Review 2.  Three questions about preconditioning.

Authors:  M Connaughton; D J Hearse
Journal:  Basic Res Cardiol       Date:  1996 Jan-Feb       Impact factor: 17.165

Review 3.  Cardiac nuclear medicine, present status, future hopes as seen from the view of a cardiologist.

Authors:  P R Lichtlen
Journal:  Eur J Nucl Med       Date:  1988

4.  Differential potentiation by depolarization of the effects of calcium antagonists on contraction and Ca2+ current in guinea-pig heart.

Authors:  R Okuyama; S Adachi-Akahane; T Nagao
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

Review 5.  The pathophysiology and epidemiology of myocardial infarction. A review.

Authors:  J Gill
Journal:  Drugs       Date:  1991       Impact factor: 9.546

6.  Reperfusion after acute coronary occlusion in dogs impairs endothelium-dependent relaxation to acetylcholine and augments contractile reactivity in vitro.

Authors:  K M VanBenthuysen; I F McMurtry; L D Horwitz
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

7.  Limitation of myocardial necrosis with verapamil during sustained coronary occlusion in the closed-chest dog.

Authors:  J G Kingma; D M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 8.  The combination of antianginal drugs: effects and indications.

Authors:  P R Lichtlen
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

9.  Effect of lacidipine on ischaemic and reperfused isolated rabbit hearts.

Authors:  A Boraso; A Cargnoni; L Comini; G Gaia; P Bernocchi; R Ferrari
Journal:  Mol Cell Biochem       Date:  1993-08-11       Impact factor: 3.396

10.  Prolonged protective effect of the calcium antagonist anipamil on the ischemic reperfused rabbit myocardium: comparison with verapamil.

Authors:  R Ferrari; R Raddino; C Ceconi; S Curello; S Ghielmi; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.